CBD

CBD is the second cannabinoid most people can name, and the one most likely to be described in terms the evidence does not support.

What it is

Cannabidiol is a phytocannabinoid, C₂₁H₃₀O₂, and it is not meaningfully intoxicating. It does not produce the effects THC does, at any dose you are likely to encounter.

In the plant it exists mostly as CBDA, an acid precursor that converts to CBD when heated. That conversion is why the arithmetic on a lab report is not straightforward.

Unlike most cannabinoids, CBD has been through the full pharmaceutical process: a purified formulation is an approved prescription medicine in the United States and elsewhere for specific, narrow seizure disorders, following controlled trials. That is a real and unusual level of evidence — and it is evidence about a purified drug at pharmaceutical doses for named conditions, not about the CBD content of a cannabis product.

What you will see on a COA

"Total CBD" on a lab report is a calculated figure, not a measurement:

Total CBD = CBD + (CBDA × 0.877)

The 0.877 factor accounts for the mass the molecule loses when the carboxyl group leaves during heating. The same arithmetic applies to THCA and THC — see THC:CBD ratios explained for how the two totals relate.

The practical read: an already-decarboxylated product such as a tincture, capsule, or edible delivers close to its stated total. Flower delivers something less, varying with how completely it was heated.

Concentrations vary enormously by product category. Hemp-derived flower can run 5% to 20% or higher. Most adult-use cannabis flower carries CBD below the limit of detection, and balanced cultivars sit anywhere between. Edibles and tinctures are usually dosed in milligrams rather than percentages, which is not interchangeable with a percentage without knowing the serving size.

What the research does and does not show

CBD is the cannabinoid where the gap between what is established and what is marketed is widest, in both directions.

Well established: the prescription formulation's approved indication, backed by randomised controlled trials — for a purified drug at pharmaceutical doses, not for anything sold as a cannabis product. The interaction with THC — CBD demonstrably modulates some of THC's subjective effects in controlled human studies, with the direction depending on dose and ratio. And a real drug-interaction profile: CBD is metabolised in the liver and affects CYP enzymes, including CYP3A4 and CYP2C19, which are the same enzymes that clear a long list of common medications. This is the part of the CBD story that gets the least attention and deserves the most, particularly with oral products. If you take prescription medication, this is a question for a pharmacist rather than a product label.

Not established: essentially every consumer-facing outcome claim attached to CBD in retail. There is a broad literature of preclinical work and early human studies across a range of areas, some of it promising, much of it small, uncontrolled, or open-label. Confidence in the retail claims runs well ahead of the data behind them.

There is also a dose mismatch that is rarely acknowledged. Trial doses in the clinical work are frequently in the hundreds of milligrams per day. A retail product delivering 10 or 25mg is a different proposition, and the trial results do not transfer to it.

How to actually find out

CBD is one of the easier compounds to track, because it is printed clearly and because products vary in it deliberately rather than incidentally.

To make your own record answer the question:

• Record milligrams, not just the percentage or the ratio. Scale is the variable that the ratio hides and that the research suggests matters.
• Do not mix routes. Oral and inhaled CBD differ substantially in onset, duration, and interaction potential. A comparison that blends them is comparing two things at once.
• Note the rest of the product. A CBD figure without the THC figure and the terpene profile beside it describes a fraction of what you consumed.
• Give it enough sessions and enough products. CBD is heavily marketed, and expectation shapes experience. Volume and variety are what let a pattern survive that.

The literature describes averages across groups of people under conditions unlike yours. Your own record, kept honestly and over enough sessions, can answer a question the literature currently cannot: whether CBD content tracks anything in your sessions.